Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indevus/Pliva Sanctura For Overactive Bladder Clears FDA; Third Quarter Launch Planned

This article was originally published in The Pink Sheet Daily

Executive Summary

Indevus and Pliva will detail trospium with a sales force of approximately 480 reps under a co-promotion deal signed in April. The companies will face marketing powerhouses Pfizer (Detrol LA) and J&J (Ditropan XL).

You may also be interested in...



Sanctura XR NDA Filing On Target For Year-End

Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.

Sanctura XR NDA Filing On Target For Year-End

Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.

Indevus To Market Nebido In The U.S. Upon Approval

Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.

Related Content

Topics

UsernamePublicRestriction

Register

PS059550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel